Free Trial

Neurocrine Biosciences (NBIX) Stock Price, News & Analysis

Neurocrine Biosciences logo
$133.46 -1.46 (-1.08%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$129.88 -3.58 (-2.68%)
As of 07/11/2025 07:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Neurocrine Biosciences Stock (NASDAQ:NBIX)

Key Stats

Today's Range
$132.10
$135.00
50-Day Range
$109.75
$134.92
52-Week Range
$84.23
$157.98
Volume
724,778 shs
Average Volume
1.15 million shs
Market Capitalization
$13.21 billion
P/E Ratio
45.24
Dividend Yield
N/A
Price Target
$163.91
Consensus Rating
Moderate Buy

Company Overview

Neurocrine Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
91st Percentile Overall Score

NBIX MarketRank™: 

Neurocrine Biosciences scored higher than 91% of companies evaluated by MarketBeat, and ranked 103rd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Neurocrine Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on 20 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Neurocrine Biosciences has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Neurocrine Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Neurocrine Biosciences are expected to grow by 51.17% in the coming year, from $4.28 to $6.47 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Neurocrine Biosciences is 45.24, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.85.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Neurocrine Biosciences is 45.24, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.26.

  • Price to Earnings Growth Ratio

    Neurocrine Biosciences has a PEG Ratio of 1.37. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Neurocrine Biosciences has a P/B Ratio of 5.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Neurocrine Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    3.75% of the float of Neurocrine Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Neurocrine Biosciences has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Neurocrine Biosciences has recently increased by 0.86%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Neurocrine Biosciences does not currently pay a dividend.

  • Dividend Growth

    Neurocrine Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.75% of the float of Neurocrine Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Neurocrine Biosciences has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Neurocrine Biosciences has recently increased by 0.86%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Neurocrine Biosciences has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 31 news articles for Neurocrine Biosciences this week, compared to 17 articles on an average week.
  • Search Interest

    5 people have searched for NBIX on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Neurocrine Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $14,978,602.00 in company stock.

  • Percentage Held by Insiders

    Only 4.80% of the stock of Neurocrine Biosciences is held by insiders.

  • Percentage Held by Institutions

    92.59% of the stock of Neurocrine Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Neurocrine Biosciences' insider trading history.
Receive NBIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter.

NBIX Stock News Headlines

Banks aren’t ready for this altcoin—are you?
The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket change.
Futuristic laboratory, doctor or scientist holding glass tube, molecular and DNA structure, genetic research human biology and pharmaceutical technology, medical,science,development biological system — Photo
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking (NBIX)
Timing matters with biotech stocks; these three companies offer distinct risk-reward profiles but have upcoming catalysts that could redefine their value...
See More Headlines

NBIX Stock Analysis - Frequently Asked Questions

Neurocrine Biosciences' stock was trading at $136.50 on January 1st, 2025. Since then, NBIX stock has decreased by 2.2% and is now trading at $133.46.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) posted its quarterly earnings data on Monday, May, 5th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.70 by $0.62. Neurocrine Biosciences's revenue was up 11.1% on a year-over-year basis.
Read the conference call transcript
.

Neurocrine Biosciences' Board of Directors authorized a stock buyback program on Friday, February 21st 2025, which allows the company to repurchase $500,000,000 in outstanding shares, according to EventVestor. This means that the company could purchase up to 4.2% of its shares through open market purchases. Shares buyback programs are usually a sign that the company's board of directors believes its stock is undervalued.

Top institutional shareholders of Neurocrine Biosciences include Swedbank AB (0.51%), Assenagon Asset Management S.A. (0.06%), IFM Investors Pty Ltd (0.02%) and Wealth Enhancement Advisory Services LLC (0.02%). Insiders that own company stock include Neurocrine Biosciences Inc, Kevin Charles Gorman, Kyle Gano, Gary A Lyons, Eric Benevich, William H Rastetter, Darin Lippoldt, Matt Abernethy, Richard F Pops, Stephen A Sherwin, Eiry Roberts, Julie Cooke, Malcolm Lloyd-Smith, Jude Onyia, David W Boyer, Ingrid Delaet, Shalini Sharp, Leslie V Norwalk and George J Morrow.
View institutional ownership trends
.

Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Neurocrine Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Humana (HUM), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW).

Company Calendar

Last Earnings
5/05/2025
Today
7/13/2025
Next Earnings (Estimated)
7/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:NBIX
CIK
914475
Employees
1,800
Year Founded
N/A

Price Target and Rating

High Price Target
$219.00
Low Price Target
$115.00
Potential Upside/Downside
+22.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.87
Research Coverage
23 Analysts

Profitability

EPS (Trailing Twelve Months)
$2.95
Trailing P/E Ratio
45.24
Forward P/E Ratio
31.18
P/E Growth
1.37
Net Income
$341.30 million
Net Margins
12.68%
Pretax Margin
19.32%
Return on Equity
11.81%
Return on Assets
8.59%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.13
Quick Ratio
3.02

Sales & Book Value

Annual Sales
$2.36 billion
Price / Sales
5.61
Cash Flow
$3.38 per share
Price / Cash Flow
39.49
Book Value
$25.58 per share
Price / Book
5.22

Miscellaneous

Outstanding Shares
98,970,000
Free Float
94,216,000
Market Cap
$13.21 billion
Optionable
Optionable
Beta
0.24

Social Links

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:NBIX) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners